Table 1 Characteristics of biliary tract cancer patients
Characteristic | Total (n = 92) | Adjuvant CCRT (n = 46) | Adjuvant chemotherapy (n = 46) | P value |
|---|---|---|---|---|
Median age, years (range) | 64.5 (34–81) | 65.5 (44–81) | 61.0 (34–80) | 0.134 |
Men (%) | 58 (63.0) | 26 (56.5) | 32 (69.6) | 0.195 |
Performance (%) | ||||
KPS ≥70 | 83 (90.2) | 41 (89.1) | 42 (91.3) | 1.000 |
KPS < 70 | 9 (9.8) | 5 (10.9) | 4 (8.7) | |
Comorbidities (%) | ||||
CCI < 3 | 50 (54.3) | 24 (52.2) | 26 (56.5) | 0.675 |
CCI ≥3 | 42 (45.7) | 22 (47.8) | 20 (43.5) | |
Tumor location (%) | ||||
Intrahepatic bile duct | 13 (14.1) | 6 (13.0) | 7 (15.2) | 0.756 |
Perihilar bile duct | 17 (18.5) | 10 (21.7) | 7 (15.2) | |
Distal bile duct | 42 (45.7) | 19 (41.3) | 23 (50.0) | |
Gallbladder | 20 (21.7) | 11 (23.9) | 9 (19.6) | |
Histology (%) | ||||
Adenocarcinoma | 86 (93.5) | 43 (93.5) | 43 (93.5) | 1.000 |
Others | 6 (6.5) | 3 (6.5) | 3 (6.5) | |
Grade (%) | ||||
Well | 4 (4.3) | 1 (2.2) | 3 (6.5) | 0.590 |
Moderate | 63 (68.5) | 32 (69.6) | 31 (67.4) | |
Poor | 21 (22.8) | 12 (26.1) | 9 (19.6) | |
NA | 4 (4.3) | 1 (2.2) | 3 (6.5) | |
LV invasion (%) | ||||
Yes | 64 (69.6) | 29 (63.0) | 35 (76.1) | 0.213 |
No | 25 (27.2) | 15 (32.6) | 10 (21.7) | |
NA | 3 (3.3) | 2 (4.3) | 1 (2.2) | |
Perineural invasion (%) | ||||
Yes | 65 (70.7) | 34 (73.9) | 31 (67.4) | 0.414 |
No | 14 (15.2) | 9 (19.6) | 5 (10.9) | |
NA | 13 (14.1) | 3 (6.5) | 10 (21.7) | |
pT stage (%) | ||||
1 | 10 (10.9) | 3 (6.5) | 7 (15.2) | 0.279 |
2 | 39 (42.4) | 21 (45.7) | 18 (39.1) | |
3 | 41 (44.6) | 22 (47.8) | 19 (41.3) | |
4 | 2 (2.2) | 0 (0.0) | 2 (4.3) | |
LN involvement (%) | ||||
Yes | 54 (58.7) | 26 (56.5) | 28 (60.9) | 0.672 |
No | 38 (41.3) | 20 (43.5) | 18 (39.1) | |
Pathologic stage (%) | ||||
I | 14 (15.2) | 5 (10.9) | 9 (19.6) | 0.611 |
II | 37 (40.2) | 19 (41.3) | 18 (39.1) | |
III | 28 (30.4) | 16 (34.8) | 12 (26.1) | |
IVa | 13 (14.1) | 6 (13.0) | 7 (15.2) | |
Resection margin (%) | ||||
Negative | 45 (48.9) | 16 (34.8) | 29 (63.0) | 0.007 |
Positive | 47 (51.1) | 30 (65.2) | 17 (37.0) | |
CA19–9 (%) | ||||
< 37 U/ml | 35 (38.0) | 16 (34.8) | 19 (41.3) | 0.697 |
≥37 U/ml | 50 (54.3) | 25 (54.3) | 25 (54.3) | |
NA | 7 (7.6) | 5 (10.9) | 2 (4.3) | |
Recurrence (%) | ||||
No | 19 (20.7) | 18 (39.1) | 1 (2.2) | 0.123 |
Locoregional | 22 (23.9) | 6 (13.0) | 16 (34.8) | |
Distant | 36 (39.1) | 13 (28.3) | 23 (50.0) | |
Both | 15 (16.3) | 9 (19.6) | 6 (13.0) | |